| Identification | Back Directory | [Name]
N-[2-[1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]acetamide | [CAS]
253168-86-4 | [Synonyms]
rac-Apremilast
(+/-)-Apremilast
Apremilast Impurity 70
N-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide
N-[2-[1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]acetamide
Acetamide, N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]- | [Molecular Formula]
C22H24N2O7S | [MDL Number]
MFCD22543851 | [MOL File]
253168-86-4.mol | [Molecular Weight]
460.5 |
| Chemical Properties | Back Directory | [Boiling point ]
741.3±60.0 °C(Predicted) | [density ]
1.381±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
14.01±0.20(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
(Rac)-Apremilast ((Rac)-CC-10004) is the racemic mixture of Apremilast. (Rac)-Apremilast has anti-inflammatory properties and can be used for research on inflammatory diseases, such as psoriasis[1][2]. | [IC 50]
hPDE4D: 0.3 nM (IC50) | [References]
[1] Armstrong AW, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023 Jan;88(1):29-39. DOI:10.1016/j.jaad.2022.07.002
[2] Man H W, et al. Discovery of (S)-N-{2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1, 3-dioxo-2, 3-dihydro-1 H-isoindol-4-yl} acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-α inhibitor[J]. Journal of medicinal chemistry, 2009, 52(6): 1522-1524. |
|
|